Q-Line Biotech IPO

Incorporated in 2010, Q-Line Biotech Ltd. is engaged in the business of developing, manufacturing and marketing a diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, and distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through our distributor/s majorly to diagnostic service providers, hospitals and medical colleges. The company's key manufacturing segments include indigenous manufacturing of reagents (Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics, and Others [POC Devices & Rapid Tests]) and supplying/manufacturing of in-vitro diagnostics (IVD) and Pathology equipment & devices. As of December 31, 2025, the total annual capacity was about 1.4 million kits (Haematology, Clinical Chemistry, Rapid/Elisa) and 1,200 Selectra Machines. As of March 31, 2026, the manufacturing teams include 126 employees and 223 third-party workers collaborating with R&D, supply chain, and external partners to meet benchmarks. Competitive Strengths: Established manufacturing capabilities with focus on R&D, Reverse Engineering and quality control. Diversified product portfolio with focus on IVD industry Widespread distribution network with a presence across all four regions. Long standing relationships with customers. Experienced Promoter and Management team

Information on this page is for general awareness only and is not investment advice. Grey market premium (when shown) is unofficial and indicative. Always read the RHP/DRHP and consult a qualified adviser before investing.